Company intelligence / Profile preview

KOLPharma

Ownership: Private
Development stage: Other

Overview

KOL Pharma is an Italian pharmaceutical company dedicated to the research, development, and commercialization of innovative therapies for rare and neglected diseases. The company focuses on addressing high unmet medical needs in niche therapeutic areas such as cystic fibrosis and metabolic disorders. Its lead development program, KOL-0612, is a small molecule candidate currently being evaluated for the treatment of cystic fibrosis. KOL Pharma leverages a network of scientific collaborations to advance its pipeline of orphan drugs. The company is headquartered in Rome, Italy, within the Castel Romano research hub.

Therapeutic areas: PulmonologyRare DiseasesMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on KOLPharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KOLPharma.